Autoimmune Pancreatitis in Europe: Clinical Profile and
Response to Treatment

a 2022

Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment

OVERBEEK, Kasper A, J POULSEN, M LANZILLOTTA, O VINGE-HOLMQUIST, P MACINGA et. al.

Basic information

Original name

Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment

Authors

OVERBEEK, Kasper A, J POULSEN, M LANZILLOTTA, O VINGE-HOLMQUIST, P MACINGA, A DEMIRCI, D SINDHUNATA, J BACKHUS, H ALGÜL, J BUIJS, P LEVY, M KIRIUKOVA, E GONI, M HOLLENBACH, R MIKSCH, Lumír KUNOVSKÝ, M VUJASINOVIC, S NIKOLIC, L DICKERSON, M HIRTH, M NEURATH, M ZUMBLICK, J VILA, M JALAL, G BEYER, F FROST, S CARRARA, Zdeněk KALA, Petr JABANDŽIEV, G SISMAN, F AKYUZ, G CAPURSO, M FALCONI, A ARLT, F VLEGGAAR, L BARRESI, B GREENHALF, L CZAKÓ, P HEGYI, A HOPPER, M NAYAR, T GRESS, F VITALI, A SCHNEIDER, C HALLORAN, Jan TRNA, A OKHLOBYSTIN, L DAGNA, D CAHEN, D BORDIN, V REBOURS, J MAYERLE, A KAHRAMAN, S RASCH, E CULVER, A KLEGER, E MARTÍNEZ-MONEO, O RØKKE, T HUCL, S OLESEN, M BRUNO, E DELLA-TORRE, U BEUERS, J LÖHR and J ROSENDAHL

Edition

54th meeting of the European Pancreatic Club, 2022

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30219 Gastroenterology and hepatology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.600

Organization unit

Faculty of Medicine

ISSN

DOI

http://dx.doi.org/10.1016/j.pan.2022.06.036

UT WoS

999

Abstract

V originále

Introduction: Autoimmune pancreatitis (AIP) is a rare disease. Large-scale studies from Europe are lacking, and there is little evidence on the optimum treatment regimen. Purpose: To characterize AIP patients in a large pan-European cohort, study the effectiveness of current treatment regimens, and compare these to non-European cohorts. Materials and methods: We retrospectively analyzed all adults diagnosed since 2005 with AIP type 1 or not-otherwise-specified, who had not undergone pancreatic surgery, in 40 European university hospitals. Results: We screened 1079 individuals with suspected AIP, and included 735 for analysis (69% male; median age 57 years; 85% Caucasian). Rates of complete remission were 61% for those untreated (58/95) and 72% for steroid treatment (454/631). Rates of any remission (complete or partial) were 80% (76/95) for the untreated and 96% (603/631) for steroid-treated patients. Higher steroid doses were not more effective than lower doses (OR 0.428; 95%CI 0.054-3.387) and neither was a starting dose duration longer than two weeks (OR 0.908; 95%CI 0.818-1.009). Elevated IgG4 levels independently decreased the chance of complete remission (OR 0.639; 95%CI 0.427-0.955). Relapse occurred in 30% of patients. Relapses within 6 months of remission induction were independent of the steroid tapering duration, remission induction treatment duration, and total cumulative dose. Conclusions: European AIP patients display a slightly different demography, but the same presentation and course of disease as non-European populations. Their response to steroid treatment seems slightly lower. Patients with an elevated IgG4 level may need closer monitoring during remission induction. For remission induction, a starting dose of 0.4 mg/kg/day with a minimum of 20 mg for 2 weeks is an effective treatment regimen and there is no evidence to support more aggressive regimens.

Citovat

@proceedings{2233423,
   author = {Overbeek, Kasper A and Poulsen, J and Lanzillotta, M and VingeandHolmquist, O and Macinga, P and Demirci, A and Sindhunata, D and Backhus, J and Algül, H and Buijs, J and Levy, P and Kiriukova, M and Goni, E and Hollenbach, M and Miksch, R and Kunovský, Lumír and Vujasinovic, M and Nikolic, S and Dickerson, L and Hirth, M and Neurath, M and Zumblick, M and Vila, J and Jalal, M and Beyer, G and Frost, F and Carrara, S and Kala, Zdeněk and Jabandžiev, Petr and Sisman, G and Akyuz, F and Capurso, G and Falconi, M and Arlt, A and Vleggaar, F and Barresi, L and Greenhalf, B and Czakó, L and Hegyi, P and Hopper, A and Nayar, M and Gress, T and Vitali, F and Schneider, A and Halloran, C and Trna, Jan and Okhlobystin, A and Dagna, L and Cahen, D and Bordin, D and Rebours, V and Mayerle, J and Kahraman, A and Rasch, S and Culver, E and Kleger, A and MartínezandMoneo, E and Røkke, O and Hucl, T and Olesen, S and Bruno, M and DellaandTorre, E and Beuers, U and Löhr, J and Rosendahl, J},
   booktitle = {54th meeting of the European Pancreatic Club},
   doi = {http://dx.doi.org/10.1016/j.pan.2022.06.036},
   language = {eng},
   title = {Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment},
   url = {https://www.sciencedirect.com/science/article/pii/S1424390322002319},
   year = {2022}
}

TY  - CONF
ID  - 2233423
AU  - Overbeek, Kasper A - Poulsen, J - Lanzillotta, M - Vinge-Holmquist, O - Macinga, P - Demirci, A - Sindhunata, D - Backhus, J - Algül, H - Buijs, J - Levy, P - Kiriukova, M - Goni, E - Hollenbach, M - Miksch, R - Kunovský, Lumír - Vujasinovic, M - Nikolic, S - Dickerson, L - Hirth, M - Neurath, M - Zumblick, M - Vila, J - Jalal, M - Beyer, G - Frost, F - Carrara, S - Kala, Zdeněk - Jabandžiev, Petr - Sisman, G - Akyuz, F - Capurso, G - Falconi, M - Arlt, A - Vleggaar, F - Barresi, L - Greenhalf, B - Czakó, L - Hegyi, P - Hopper, A - Nayar, M - Gress, T - Vitali, F - Schneider, A - Halloran, C - Trna, Jan - Okhlobystin, A - Dagna, L - Cahen, D - Bordin, D - Rebours, V - Mayerle, J - Kahraman, A - Rasch, S - Culver, E - Kleger, A - Martínez-Moneo, E - Røkke, O - Hucl, T - Olesen, S - Bruno, M - Della-Torre, E - Beuers, U - Löhr, J - Rosendahl, J
PY  - 2022
TI  - Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment
UR  - https://www.sciencedirect.com/science/article/pii/S1424390322002319
N2  - Introduction: Autoimmune pancreatitis (AIP) is a rare disease. Large-scale studies from Europe are lacking, and there is little evidence on the optimum treatment regimen. Purpose: To characterize AIP patients in a large pan-European cohort, study the effectiveness of current treatment regimens, and compare these to non-European cohorts. Materials and methods: We retrospectively analyzed all adults diagnosed since 2005 with AIP type 1 or not-otherwise-specified, who had not undergone pancreatic surgery, in 40 European university hospitals. Results: We screened 1079 individuals with suspected AIP, and included 735 for analysis (69% male; median age 57 years; 85% Caucasian). Rates of complete remission were 61% for those untreated (58/95) and 72% for steroid treatment (454/631). Rates of any remission (complete or partial) were 80% (76/95) for the untreated and 96% (603/631) for steroid-treated patients. Higher steroid doses were not more effective than lower doses (OR 0.428; 95%CI 0.054-3.387) and neither was a starting dose duration longer than two weeks (OR 0.908; 95%CI 0.818-1.009). Elevated IgG4 levels independently decreased the chance of complete remission (OR 0.639; 95%CI 0.427-0.955). Relapse occurred in 30% of patients. Relapses within 6 months of remission induction were independent of the steroid tapering duration, remission induction treatment duration, and total cumulative dose. Conclusions: European AIP patients display a slightly different demography, but the same presentation and course of disease as non-European populations. Their response to steroid treatment seems slightly lower. Patients with an elevated IgG4 level may need closer monitoring during remission induction. For remission induction, a starting dose of 0.4 mg/kg/day with a minimum of 20 mg for 2 weeks is an effective treatment regimen and there is no evidence to support more aggressive regimens.
ER  -

Detailed Information on Publication Record